REGISTER
First-in-Class Targeted Therapy for Primary MN Approved, Sets New Treatment Standard
On June 9, 2026, obinutuzumab β, a domestically developed novel drug for primary membranous nephropathy, was approved in China. Prof. Minghui Zhao of Peking University First Hospital noted that this represents a breakthrough as it is the first drug globally to achieve positive Phase III results and approval in membranous nephropathy, with a complete remission rate of 57.1% at Week 104 and no observed relapse during follow-up.

The domestically developed novel drug obinutuzumab β for primary membranous nephropathy was approved on June 9, 2026. In response, Prof. Minghui Zhao, MD, PhD, Director of the Renal Division at Peking University First Hospital and Director of Peking University Institute of Nephrology, stated that strong support from national policies for innovative drug development, rapid approval of breakthrough products, and the deep integration of clinical needs with novel drug R&D have truly addressed patients' pain points.

Prof. Zhao: For decades, there has been a global lack of specific therapeutic drugs for membranous nephropathy. Obinutuzumab β is the first drug worldwide to achieve positive Phase III results and receive approval for membranous nephropathy. Membranous nephropathy is an autoimmune kidney disease in which the immune system mistakenly attacks the glomerular filtration membrane, leading to impaired renal filtration function and massive proteinuria loss. Typical manifestations include foamy urine, severe edema, hypoalbuminemia, and hyperlipidemia. The disease has an insidious onset and is asymptomatic in early stages; if poorly controlled, approximately one-third of patients will progress to end-stage renal disease [1].

Prof. Zhao Cui: The treatment of membranous nephropathy has historically faced three major clinical challenges: first, some traditional immunosuppressive regimens have a relatively slow onset of action; second, the depth of remission is insufficient, making the disease prone to relapse; and third, some traditional drugs carry safety burdens.

Prof. Zhao: The study results showed that at Week 104, the complete remission rate in the obinutuzumab β group reached 57.1% [2], significantly outperforming traditional treatment regimens and achieving deep remission. Most patients showed clear improvement in proteinuria and edema within a relatively short time after treatment. Clinical study results showed a median time to immunologic remission of 1.2 months and a median time to clinical remission of 3.8 months. During the follow-up period from Week 52 to Week 104, no relapse was observed in patients after remission [3], which is of great significance for membranous nephropathy. These results indicate that for the first time, we are truly approaching long-term disease-free remission in membranous nephropathy.

Prof. Cui: The remarkable efficacy of this study is attributable to a clearer understanding of disease mechanisms and more precise therapeutic targets. Obinutuzumab β precisely targets CD20-positive B cells, reducing the production of pathogenic autoantibodies at the source, promoting immunologic remission first, followed by clinical remission. Through glycoengineering, its binding capacity to immune effector cells is enhanced, improving antibody-dependent cellular cytotoxicity (ADCC). Additionally, this Type II antibody has a stronger direct ability to induce B-cell death. These features collectively contribute to more thorough and deeper B-cell depletion [4].

Prof. Zhao: This marks a comprehensive upgrade of China's biopharmaceutical capabilities, enabling China to take the global lead in the field of autoimmune kidney diseases. Strong support from national policies for innovative drug development, rapid approval of breakthrough products, and the deep integration of clinical needs with novel drug R&D have truly addressed patients' pain points.

Prof. Cui: The significance of this achievement lies not only in bringing a new treatment option to Chinese patients with membranous nephropathy, but also in demonstrating to the international academic community China's capability and strength in conducting high-quality clinical research in the field of nephrology.

References

[1] Floege J, Amann K. Primary glomerulonephritides. Lancet. 2016;387(10032):2036-2048. doi:10.1016/S0140-6736(16)00272-5

[2] Obinutuzumab β Injection Package Insert, Beijing Mabworks Biotech Co., Ltd.

[3] Phase III Registration Clinical Study Data of Obinutuzumab β for Primary Membranous Nephropathy (unpublished, for academic exchange only).

[4] Wu L, Wei M, Gao F, et al. Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial[J]. Neurology and Therapy, 2026: 1-18.

0
0
Loading